Sarepta data suggest 3-year benefit in muscular dystrophy
July 10, 2014 at 08:32 AM EDT
Data from a study of Sarepta Therapeutics' experimental drug eteplirsen for Duchenne muscular dystrophy suggest it helped slow declines in walking ability for almost three years.
